Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04866940
Recruiting Not applicable

Validation and Implementation of 3T MRI Research Protocols

NCT04866940 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Not applicable
Started
2021-05-12
Last updated
2026-02-18

Condition(s) studied

Magnetic Resonance Imaging

Investigational drug(s) / intervention(s)

Sequences test

Sequences test: the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols

Study summary

The Philips 3T imager installed on the Pavillon Baudot site is an imager dedicated solely to research. It is not located in hospital premises but in INSERM premises for which an authorization for biomedical research has been granted. This equipment is part of the Technical Platform of the UMR 1214 ToNIC whose main objective is the study of the human brain and the main pathologies that affect it.

MRI is an evolving technique, which is used in many research projects. Our technical platform must follow these developments and remain at the cutting edge. One of the essential services of our technical platform is to help set up research protocols and validate acquisition sequences. This development activity is therefore located upstream of research projects involving clinical or fundamental applications. The fact that we can provide our users with a regulatory framework to carry out these development tests for their Research Involving Human Subjects project is a necessity for our research support activity.

This study aims to provide a generic framework to test the feasibility of MRI sequences requested within the framework of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of the images obtained.

In France, there are just over 35 centers with MRI dedicated to research and therefore with a validation protocol allowing them to validate their sequences.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female, 18 years of age or older * Ability to cooperate and remain motionless for up to 1 hour (and lying down for 1.5 hours) * Ability to understand the instructions given * Subject who has given written and informed consent prior to any examination required by the research) * Subject affiliated to a social security system or benefiting from an equivalent system Exclusion Criteria: * Persons deprived of liberty by judicial or administrative decision * Psychiatric disorders, disorders of cognitive functions, not allowing the realization of the MRI * Protected adults (subject to a measure of legal protection) or unable to express their consent * Subject with Contraindications to MRI

Primary outcome measure(s)

  • in general — at the end of studies ((i.e. one hour and a half including the installation and the delays between the sequences). Each sequence lasts between 5 and 20 minutes.
    optimization of parameters acquisition in order to suppress artefact

Trial sites (1)

FacilityCityRegionStatus
UMR 1214 ToNIC INSERM Toulouse France Recruiting

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder Active, not recruiting
Brain Injury and Cognitive Function Active, not recruiting
TMS-based Assessment of Mental Training Effects on Motor Learning in Healthy Participants Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease Starting soon
Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects Recruiting

Other trials for the same condition

Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations Recruiting
ENDOMETRIOSIS - MRI Recruiting
Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04866940 on ClinicalTrials.gov ↗ ← All trials in France